Literature DB >> 12164661

Oral mucosal immunity and HIV infection: current status.

S J Challacombe1, S P Sweet.   

Abstract

There is a paradox that profound HIV-induced immunodeficiency is present systemically, whereas the majority of infections associated with HIV disease are present or initiated at mucosal surfaces. There is therefore a need to understand both specific and non-specific mechanisms of mucosal protection against HIV and its copathogens. The majority of HIV infections occur as a result of the passage of virus across mucosal membranes. Resistance to HIV infection at mucosal surfaces may be related to HIV-specific CD8+ T cell responses in some individuals and may be the basis for protective vaccine design. However, T-cells, macrophages and dendritic cells in mucosa may be a portal of entry for HIV. Transcytosis of HIV can occur from the mucosal to the submucosal surface and vice versa, and may be inhibited by mucosal immunoglobulins and neutralizing IgA within epithelial cells. HIV-induced alterations to oral epithelial cells, together with impairment of mucosal CD4+ T-cells and consequent altered cytokine secretion, may contribute to secondary infections. It also appears that HIV infection is associated with decreased salivary IgA levels, although a dichotomy between IgA concentrations in saliva and serum has been reported. Mucosal antibody responses, however, seem to be maintained. Considerable attention has been given to the possibility of mucosal immunization against HIV and there is evidence that secretory IgA antibody is neutralizing to different HIV strains. In addition to specific immune factors, it is likely that innate nonspecific factors may be significant in protecting mucosal surfaces, including lactoferrin, secretory leukocyte protease inhibitor, mucins, proline rich proteins and cystatins. These may be useful candidate virucides in topical preparations. Thus humoral, cellular and innate immune mechanisms, as well as lymphocyte-epithelial interactions, may all be impaired at mucosal surfaces as a result of HIV infection and may contribute to the susceptibility of mucosa to infective processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12164661     DOI: 10.1034/j.1601-0825.2002.00013.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  14 in total

1.  Oral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy.

Authors:  Wipawee Nittayananta; Marisa Kemapunmanus; Korntip Amornthatree; Sineepat Talungchit; Hutcha Sriplung
Journal:  J Oral Pathol Med       Date:  2012-06-09       Impact factor: 4.253

Review 2.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

3.  Heightened cytotoxic responses and impaired biogenesis contribute to early pathogenesis in the oral mucosa of simian immunodeficiency virus-infected rhesus macaques.

Authors:  Michael D George; David Verhoeven; Sumathi Sankaran; Tiffany Glavan; Elizabeth Reay; Satya Dandekar
Journal:  Clin Vaccine Immunol       Date:  2008-12-17

4.  Sampling human indigenous saliva peptidome using a lollipop-like ultrafiltration probe: simplify and enhance peptide detection for clinical mass spectrometry.

Authors:  Wenhong Zhu; Richard L Gallo; Chun-Ming Huang
Journal:  J Vis Exp       Date:  2012-08-07       Impact factor: 1.355

5.  Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Authors:  Jessica S Thomas; Nedra Lacour; Pamela A Kozlowski; Steve Nelson; Gregory J Bagby; Angela M Amedee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

Review 6.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

Review 7.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Expression of oral cytokines in HIV-infected subjects with long-term use of antiretroviral therapy.

Authors:  W Nittayananta; K Amornthatree; M Kemapunmanus; S Talungchit; H Sriplung
Journal:  Oral Dis       Date:  2013-05-30       Impact factor: 3.511

9.  A systems biology examination of the human female genital tract shows compartmentalization of immune factor expression.

Authors:  Adam Burgener; Annelie Tjernlund; Tove Kaldensjo; Max Abou; Stuart McCorrister; Garrett R Westmacott; Kenzie Mogk; Emma Ambrose; Kristina Broliden; Blake Ball
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Changes in oral cytokeratin expression in HIV-infected subjects with long-term use of HAART.

Authors:  W Nittayananta; W Mitarnun; S Talungchit; H Sriplung
Journal:  Oral Dis       Date:  2012-07-02       Impact factor: 3.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.